IFCC全球调查:循环肿瘤DNA检测实验室实践现状
国际临床化学与检验医学联合会分子诊断委员会对58家开展ctDNA检测的实验室进行问卷调查,了解分析技术、质控与报告实践。结果显示检测方法未标准化,仅45.6%实验室参加外部质量评估,样本处理与结果报告存在差异,提示需推动ctDNA分析标准化。
要点
- 87.7%参与实验室将ctDNA检测用于患者诊疗。
- 最常见检测癌种为肺癌(71.9%)、结直肠癌(52.6%)和乳腺癌(40.4%)。
- 仅45.6%实验室参加外部质量评估,检测标准化不足。
核心结论
- ctDNA分子诊断方法在不同国家和实验室间未标准化,样本制备、处理和结果报告存在差异。
- ctDNA检测在实验室间分析性能关注不足,患者诊疗中亟需标准化分析与报告。
研究设计与样本
- IFCC分子诊断委员会(C-MD)对国际开展ctDNA检测的实验室进行问卷调查。
- 共58家实验室参与,问卷涵盖分析技术、检测参数、质量保证和结果报告。
主要发现
- 87.7%的参与实验室将ctDNA检测用于患者诊疗。
- 检测癌种以肺癌(71.9%)最常见,其次为结直肠癌(52.6%)和乳腺癌(40.4%)。
- 55.4%的实验室将ctDNA分析用于治疗耐药变异的随访/监测。
- 最常分析基因为EGFR(75.8%),其次为KRAS(65.5%)和BRAF(56.9%)。
- 仅45.6%的实验室报告参加外部质量评估计划。
关键数值与推荐
- 参与实验室总数58家。
- 87.7%用于患者诊疗;肺癌71.9%、结直肠癌52.6%、乳腺癌40.4%;随访/监测耐药变异55.4%。
- EGFR 75.8%、KRAS 65.5%、BRAF 56.9%;外部质量评估参与率45.6%。
临床怎么用
- 开展ctDNA检测的实验室应关注分析性能与标准化,并积极参加外部质量评估。
- 临床解读ctDNA结果时需注意不同实验室间样本处理与报告方式可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical validity of ctDNA analysis as a diagnostic, prognostic and predictive biomarker has been demonstrated in many studies. The rapid spread of tests for the analysis of ctDNA raises questions regarding their standardization and quality assurance. The aim of this study was to provide a global overview of the test methods, laboratory procedures and quality assessment practices using ctDNA diagnostics. METHODS: The Molecular Diagnostics Committee of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC C-MD) conducted a survey among international laboratories performing ctDNA analysis. Questions on analytical techniques, test parameters, quality assurance and the reporting of findings were included. RESULTS: A total of 58 laboratories participated in the survey. The majority of the participating laboratories (87.7 %) performed testing for patient care. Most laboratories conducted their assays for lung cancer (71.9 %), followed by colorectal (52.6 %) and breast (40.4 %) cancer, and 55.4 % of the labs used ctDNA analysis for follow-up/monitoring of treatment-resistant alterations. The most frequent gene analysed was EGFR (75.8 %), followed by KRAS (65.5 %) and BRAF (56.9 %). Participation in external quality assessment programs was reported by only 45.6 % of laboratories. CONCLUSIONS: The survey indicates that molecular diagnostic methods for the analysis of ctDNA are not standardized across countries and laboratories. Furthermore, it reveals a number of differences regarding sample preparation, processing and reporting test results. Our findings indicate that ctDNA testing is being conducted without sufficient attention to analytical performance between laboratories and highlights the need for standarisation of ctDNA analysis and reporting in patient care.
引用
- Linder MW, Huggett JF, Baluchova K, et al. Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA. Clin Chim Acta. 2023. PMID: 37217114. doi:10.1016/j.cca.2023.117398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。